Skye Bioscience (SKYE) Revenue (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly Revenue of $136175.0 for Q2 2014, up 25.01% year-over-year from $108929.0 in Q2 2013, and up 64.37% quarter-over-quarter from $82845.0 in Q4 2013.
Skye Bioscience (SKYE) Revenue (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported Revenue for 2 consecutive years, with $136175.0 the latest figure, recorded in Q2 2014.
- In Q2 2014, Revenue rose 25.01% year-over-year to $136175.0; the TTM figure through Apr 2014 stood at $419101.0 (changed N/A YoY), while the FY2013 annual figure was $339926.0, up 1992.75% from the prior year.
- Revenue climbed to $136175.0 in Q2 2014 per SKYE's latest filing, from $82845.0 in the prior quarter.
- Across five years, Revenue topped out at $136175.0 in Q2 2014 and bottomed at $57130.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | 136,175.00 |
| Oct 31, 2013 | 82,845.00 |
| Jul 31, 2013 | 91,152.00 |
| Apr 30, 2013 | 108,929.00 |
| Jan 31, 2013 | 57,130.00 |